Arusoglu Latif, Reiss Nils, Morshuis Michiel, Schoenbrodt Michael, Hakim-Meibodi Kavous, Gummert Jan
Heart Center North Rhine-Westphalia, Ruhr-University of Bochum, Bad Oeynhausen, Germany.
Heart Surg Forum. 2010 Dec;13(6):E391-3. doi: 10.1532/HSF98.20101142.
The CardioWest™ total artificial heart (SynCardia Systems, Tuscon, AZ, USA) is the only FDA-approved total artificial heart determined as a bridge to human heart transplantation for patients dying of biventricular heart failure. Implantation provides immediate hemodynamic restoration and clinical stabilization, leading to end-organ recovery and thus eventually allowing cardiac transplantation. Occasionally, implantation of a total artificial heart is not feasible for anatomical reasons. For this patient group, we have developed an alternative technique using the paracorporeal Thoratec biventricular support system (Thoratec, Pleasanton, CA, USA) as a modified total artificial heart. A detailed description of the implantation technique is presented.
CardioWest™ 全人工心脏（美国亚利桑那州图森市的SynCardia Systems公司生产）是唯一经美国食品药品监督管理局（FDA）批准的全人工心脏，被确定为用于因双心室心力衰竭而濒死患者的心脏移植过渡装置。植入该装置可立即恢复血流动力学并实现临床稳定，促使终末器官恢复，最终得以进行心脏移植。偶尔，由于解剖学原因，植入全人工心脏并不可行。对于这一患者群体，我们开发了一种替代技术，即使用体外式Thoratec双心室支持系统（美国加利福尼亚州普莱森顿市的Thoratec公司生产）作为改良的全人工心脏。本文将详细介绍植入技术。
